Impact on Non-Motor Symptoms GLP-1 RAs have shown encouraging potential in addressing non-motor symptoms in PD, which are major contributors to disability and reduced quality of Life
For context on timelines with similar compounds, see our guide on semaglutide appetite suppression timelines
Trimethylamine-N-oxide (TMAO) response to animal source foods varies among healthy young men and is influenced by their gut microbiota composition: A randomized controlled trial
Research Context GH secretagogue research is studied extensively in the preclinical literature in models of pituitary endocrinology, growth-factor signaling, and somatotrope cell biology
In biochemical and cellular research models, AOD9604 is used to investigate growth hormonerelated signalling pathways that are independent of classical GH receptor activation
1 This comes as Novo Nordisk and Eli Lilly continue to aggressively challenge compounded versions of their GLP-1 medications